Christoph Waer

Summa Equity AB (Summa Equity) is a private equity firm founded in 2016 by Jenny Keisu, Reynir Kjær Indahl and Johannes Hidle Lien. The firm is headquartered in Stockholm, Sweden.

Mérieux Equity Partners SAS (Mérieux Equity Partners or MxEP) is a Private Equity and Venture Capital firm, a subsidiary of Mérieux Développement SASU founded in 2009. The firm is headquartered in Lyon, France, with additional offices across the country.

Korys Management NV is a Private Equity/Venture Capital firm, a subsidiary of Korys NV founded in 2000. Korys Management NV is headquartered in Halle.

Axion BioSystems, Inc. develops life science instrumentation and medical diagnostic equipment. The firms products include, such as MEA systems, MEA plates, AxIS software, and Lumos. The company was founded by Thomas J. O'Brien, Mark G. Allen, Swaminathan Rajaraman, Edgar Brown, Stephen P. DeWeerth and James D. Ross in May 2008 and is headquartered in Atlanta, GA.

Summa Equity AB (Summa Equity) is a private equity firm founded in 2016 by Jenny Keisu, Reynir Kjær Indahl and Johannes Hidle Lien. The firm is headquartered in Stockholm, Sweden.

Sengenics International Pte Ltd. develops arrays used in genomics research. It is a genomics and proteomics-based research and diagnostics company with a range of patented technologies and products that are marketed to pharmaceutical companies, scientists and hospitals. The firm flagship technology is the patented Immunome auto-antibody profiling platform which was spun out from research that was commercialized as a joint collaboration between the University of Oxford and the University of Cambridge. The company is headquartered in Singapore.

Summa Equity AB (Summa Equity) is a private equity firm founded in 2016 by Jenny Keisu, Reynir Kjær Indahl and Johannes Hidle Lien. The firm is headquartered in Stockholm, Sweden.

Agendia, Inc. operates as a molecular diagnostics company. It develops and markets FFPE-based genomic diagnostic products, which help support physicians with their treatment decisions. Agendia?s tests can help physicians assess a patient?s individual risk for metastasis, it benefits from chemo, hormonal or combination therapy. The company was founded by Laura van't Veer and Ren? Bernards in 2003 and is headquartered in Irvine, CA.

Axion BioSystems, Inc. develops life science instrumentation and medical diagnostic equipment. The firms products include, such as MEA systems, MEA plates, AxIS software, and Lumos. The company was founded by Thomas J. O'Brien, Mark G. Allen, Swaminathan Rajaraman, Edgar Brown, Stephen P. DeWeerth and James D. Ross in May 2008 and is headquartered in Atlanta, GA.

Summa Equity AB (Summa Equity) is a private equity firm founded in 2016 by Jenny Keisu, Reynir Kjær Indahl and Johannes Hidle Lien. The firm is headquartered in Stockholm, Sweden.

Summa Equity AB (Summa Equity) is a private equity firm founded in 2016 by Jenny Keisu, Reynir Kjær Indahl and Johannes Hidle Lien. The firm is headquartered in Stockholm, Sweden.

Summa Equity AB (Summa Equity) is a private equity firm founded in 2016 by Jenny Keisu, Reynir Kjær Indahl and Johannes Hidle Lien. The firm is headquartered in Stockholm, Sweden.

Summa Equity AB (Summa Equity) is a private equity firm founded in 2016 by Jenny Keisu, Reynir Kjær Indahl and Johannes Hidle Lien. The firm is headquartered in Stockholm, Sweden.

Summa Equity AB (Summa Equity) is a private equity firm founded in 2016 by Jenny Keisu, Reynir Kjær Indahl and Johannes Hidle Lien. The firm is headquartered in Stockholm, Sweden.

Axion BioSystems, Inc. develops life science instrumentation and medical diagnostic equipment. The firms products include, such as MEA systems, MEA plates, AxIS software, and Lumos. The company was founded by Thomas J. O'Brien, Mark G. Allen, Swaminathan Rajaraman, Edgar Brown, Stephen P. DeWeerth and James D. Ross in May 2008 and is headquartered in Atlanta, GA.

Summa Equity AB (Summa Equity) is a private equity firm founded in 2016 by Jenny Keisu, Reynir Kjær Indahl and Johannes Hidle Lien. The firm is headquartered in Stockholm, Sweden.

Mérieux Equity Partners SAS (Mérieux Equity Partners or MxEP) is a Private Equity and Venture Capital firm, a subsidiary of Mérieux Développement SASU founded in 2009. The firm is headquartered in Lyon, France, with additional offices across the country.

Axion BioSystems, Inc. develops life science instrumentation and medical diagnostic equipment. The firms products include, such as MEA systems, MEA plates, AxIS software, and Lumos. The company was founded by Thomas J. O'Brien, Mark G. Allen, Swaminathan Rajaraman, Edgar Brown, Stephen P. DeWeerth and James D. Ross in May 2008 and is headquartered in Atlanta, GA.

Summa Equity AB (Summa Equity) is a private equity firm founded in 2016 by Jenny Keisu, Reynir Kjær Indahl and Johannes Hidle Lien. The firm is headquartered in Stockholm, Sweden.

Mérieux Equity Partners SAS (Mérieux Equity Partners or MxEP) is a Private Equity and Venture Capital firm, a subsidiary of Mérieux Développement SASU founded in 2009. The firm is headquartered in Lyon, France, with additional offices across the country.

Sengenics International Pte Ltd. develops arrays used in genomics research. It is a genomics and proteomics-based research and diagnostics company with a range of patented technologies and products that are marketed to pharmaceutical companies, scientists and hospitals. The firm flagship technology is the patented Immunome auto-antibody profiling platform which was spun out from research that was commercialized as a joint collaboration between the University of Oxford and the University of Cambridge. The company is headquartered in Singapore.

Summa Equity AB (Summa Equity) is a private equity firm founded in 2016 by Jenny Keisu, Reynir Kjær Indahl and Johannes Hidle Lien. The firm is headquartered in Stockholm, Sweden.

Agendia, Inc. operates as a molecular diagnostics company. It develops and markets FFPE-based genomic diagnostic products, which help support physicians with their treatment decisions. Agendia?s tests can help physicians assess a patient?s individual risk for metastasis, it benefits from chemo, hormonal or combination therapy. The company was founded by Laura van't Veer and Ren? Bernards in 2003 and is headquartered in Irvine, CA.

Agendia, Inc. operates as a molecular diagnostics company. It develops and markets FFPE-based genomic diagnostic products, which help support physicians with their treatment decisions. Agendia?s tests can help physicians assess a patient?s individual risk for metastasis, it benefits from chemo, hormonal or combination therapy. The company was founded by Laura van't Veer and Ren? Bernards in 2003 and is headquartered in Irvine, CA.

Mérieux Equity Partners SAS (Mérieux Equity Partners or MxEP) is a Private Equity and Venture Capital firm, a subsidiary of Mérieux Développement SASU founded in 2009. The firm is headquartered in Lyon, France, with additional offices across the country.

Mérieux Equity Partners SAS (Mérieux Equity Partners or MxEP) is a Private Equity and Venture Capital firm, a subsidiary of Mérieux Développement SASU founded in 2009. The firm is headquartered in Lyon, France, with additional offices across the country.

Summa Equity AB (Summa Equity) is a private equity firm founded in 2016 by Jenny Keisu, Reynir Kjær Indahl and Johannes Hidle Lien. The firm is headquartered in Stockholm, Sweden.

Summa Equity AB (Summa Equity) is a private equity firm founded in 2016 by Jenny Keisu, Reynir Kjær Indahl and Johannes Hidle Lien. The firm is headquartered in Stockholm, Sweden.

Mérieux Equity Partners SAS (Mérieux Equity Partners or MxEP) is a Private Equity and Venture Capital firm, a subsidiary of Mérieux Développement SASU founded in 2009. The firm is headquartered in Lyon, France, with additional offices across the country.

MyCartis NV develops technologies for healthcare personalization needs. It offers Evalution, a multiplex analysis platform to develop protein and nucleic-acid based clinical biomarkers. The company provides disruptive solutions in the fields of clinical and translational research for various applications in the detection of proteins and nucleic acids, such as sandwich immunoassays, antibody assays, genotyping assays, and mutation analysis assays to customers and partners. It offers products for various disease areas, including cell signalling, cardiovascular, oncology, and preeclampsia. The company was founded by Koen Kas in August 2004 and is headquartered in Ghent, Belgium.

Agendia, Inc. operates as a molecular diagnostics company. It develops and markets FFPE-based genomic diagnostic products, which help support physicians with their treatment decisions. Agendia?s tests can help physicians assess a patient?s individual risk for metastasis, it benefits from chemo, hormonal or combination therapy. The company was founded by Laura van't Veer and Ren? Bernards in 2003 and is headquartered in Irvine, CA.

Korys Management NV is a Private Equity/Venture Capital firm, a subsidiary of Korys NV founded in 2000. Korys Management NV is headquartered in Halle.

Korys Management NV is a Private Equity/Venture Capital firm, a subsidiary of Korys NV founded in 2000. Korys Management NV is headquartered in Halle.

Korys Management NV is a Private Equity/Venture Capital firm, a subsidiary of Korys NV founded in 2000. Korys Management NV is headquartered in Halle.

Summa Equity AB (Summa Equity) is a private equity firm founded in 2016 by Jenny Keisu, Reynir Kjær Indahl and Johannes Hidle Lien. The firm is headquartered in Stockholm, Sweden.

Summa Equity AB (Summa Equity) is a private equity firm founded in 2016 by Jenny Keisu, Reynir Kjær Indahl and Johannes Hidle Lien. The firm is headquartered in Stockholm, Sweden.

Axion BioSystems, Inc. develops life science instrumentation and medical diagnostic equipment. The firms products include, such as MEA systems, MEA plates, AxIS software, and Lumos. The company was founded by Thomas J. O'Brien, Mark G. Allen, Swaminathan Rajaraman, Edgar Brown, Stephen P. DeWeerth and James D. Ross in May 2008 and is headquartered in Atlanta, GA.

Agendia, Inc. operates as a molecular diagnostics company. It develops and markets FFPE-based genomic diagnostic products, which help support physicians with their treatment decisions. Agendia?s tests can help physicians assess a patient?s individual risk for metastasis, it benefits from chemo, hormonal or combination therapy. The company was founded by Laura van't Veer and Ren? Bernards in 2003 and is headquartered in Irvine, CA.

Agendia, Inc. operates as a molecular diagnostics company. It develops and markets FFPE-based genomic diagnostic products, which help support physicians with their treatment decisions. Agendia?s tests can help physicians assess a patient?s individual risk for metastasis, it benefits from chemo, hormonal or combination therapy. The company was founded by Laura van't Veer and Ren? Bernards in 2003 and is headquartered in Irvine, CA.

Korys Management NV is a Private Equity/Venture Capital firm, a subsidiary of Korys NV founded in 2000. Korys Management NV is headquartered in Halle.

Axion BioSystems, Inc. develops life science instrumentation and medical diagnostic equipment. The firms products include, such as MEA systems, MEA plates, AxIS software, and Lumos. The company was founded by Thomas J. O'Brien, Mark G. Allen, Swaminathan Rajaraman, Edgar Brown, Stephen P. DeWeerth and James D. Ross in May 2008 and is headquartered in Atlanta, GA.

Summa Equity AB (Summa Equity) is a private equity firm founded in 2016 by Jenny Keisu, Reynir Kjær Indahl and Johannes Hidle Lien. The firm is headquartered in Stockholm, Sweden.

Summa Equity AB (Summa Equity) is a private equity firm founded in 2016 by Jenny Keisu, Reynir Kjær Indahl and Johannes Hidle Lien. The firm is headquartered in Stockholm, Sweden.

Summa Equity AB (Summa Equity) is a private equity firm founded in 2016 by Jenny Keisu, Reynir Kjær Indahl and Johannes Hidle Lien. The firm is headquartered in Stockholm, Sweden.

Agendia, Inc. operates as a molecular diagnostics company. It develops and markets FFPE-based genomic diagnostic products, which help support physicians with their treatment decisions. Agendia?s tests can help physicians assess a patient?s individual risk for metastasis, it benefits from chemo, hormonal or combination therapy. The company was founded by Laura van't Veer and Ren? Bernards in 2003 and is headquartered in Irvine, CA.

Summa Equity AB (Summa Equity) is a private equity firm founded in 2016 by Jenny Keisu, Reynir Kjær Indahl and Johannes Hidle Lien. The firm is headquartered in Stockholm, Sweden.

Agendia, Inc. operates as a molecular diagnostics company. It develops and markets FFPE-based genomic diagnostic products, which help support physicians with their treatment decisions. Agendia?s tests can help physicians assess a patient?s individual risk for metastasis, it benefits from chemo, hormonal or combination therapy. The company was founded by Laura van't Veer and Ren? Bernards in 2003 and is headquartered in Irvine, CA.

Summa Equity AB (Summa Equity) is a private equity firm founded in 2016 by Jenny Keisu, Reynir Kjær Indahl and Johannes Hidle Lien. The firm is headquartered in Stockholm, Sweden.

Summa Equity AB (Summa Equity) is a private equity firm founded in 2016 by Jenny Keisu, Reynir Kjær Indahl and Johannes Hidle Lien. The firm is headquartered in Stockholm, Sweden.

Summa Equity AB (Summa Equity) is a private equity firm founded in 2016 by Jenny Keisu, Reynir Kjær Indahl and Johannes Hidle Lien. The firm is headquartered in Stockholm, Sweden.

Summa Equity AB (Summa Equity) is a private equity firm founded in 2016 by Jenny Keisu, Reynir Kjær Indahl and Johannes Hidle Lien. The firm is headquartered in Stockholm, Sweden.

Summa Equity AB (Summa Equity) is a private equity firm founded in 2016 by Jenny Keisu, Reynir Kjær Indahl and Johannes Hidle Lien. The firm is headquartered in Stockholm, Sweden.

Agendia, Inc. operates as a molecular diagnostics company. It develops and markets FFPE-based genomic diagnostic products, which help support physicians with their treatment decisions. Agendia?s tests can help physicians assess a patient?s individual risk for metastasis, it benefits from chemo, hormonal or combination therapy. The company was founded by Laura van't Veer and Ren? Bernards in 2003 and is headquartered in Irvine, CA.

Agendia, Inc. operates as a molecular diagnostics company. It develops and markets FFPE-based genomic diagnostic products, which help support physicians with their treatment decisions. Agendia?s tests can help physicians assess a patient?s individual risk for metastasis, it benefits from chemo, hormonal or combination therapy. The company was founded by Laura van't Veer and Ren? Bernards in 2003 and is headquartered in Irvine, CA.

Korys Management NV is a Private Equity/Venture Capital firm, a subsidiary of Korys NV founded in 2000. Korys Management NV is headquartered in Halle.

Korys Management NV is a Private Equity/Venture Capital firm, a subsidiary of Korys NV founded in 2000. Korys Management NV is headquartered in Halle.

Summa Equity AB (Summa Equity) is a private equity firm founded in 2016 by Jenny Keisu, Reynir Kjær Indahl and Johannes Hidle Lien. The firm is headquartered in Stockholm, Sweden.

Korys Management NV is a Private Equity/Venture Capital firm, a subsidiary of Korys NV founded in 2000. Korys Management NV is headquartered in Halle.

Korys Management NV is a Private Equity/Venture Capital firm, a subsidiary of Korys NV founded in 2000. Korys Management NV is headquartered in Halle.

Axion BioSystems, Inc. develops life science instrumentation and medical diagnostic equipment. The firms products include, such as MEA systems, MEA plates, AxIS software, and Lumos. The company was founded by Thomas J. O'Brien, Mark G. Allen, Swaminathan Rajaraman, Edgar Brown, Stephen P. DeWeerth and James D. Ross in May 2008 and is headquartered in Atlanta, GA.

Agendia, Inc. operates as a molecular diagnostics company. It develops and markets FFPE-based genomic diagnostic products, which help support physicians with their treatment decisions. Agendia?s tests can help physicians assess a patient?s individual risk for metastasis, it benefits from chemo, hormonal or combination therapy. The company was founded by Laura van't Veer and Ren? Bernards in 2003 and is headquartered in Irvine, CA.

Mérieux Equity Partners SAS (Mérieux Equity Partners or MxEP) is a Private Equity and Venture Capital firm, a subsidiary of Mérieux Développement SASU founded in 2009. The firm is headquartered in Lyon, France, with additional offices across the country.

Mérieux Equity Partners SAS (Mérieux Equity Partners or MxEP) is a Private Equity and Venture Capital firm, a subsidiary of Mérieux Développement SASU founded in 2009. The firm is headquartered in Lyon, France, with additional offices across the country.

Summa Equity AB (Summa Equity) is a private equity firm founded in 2016 by Jenny Keisu, Reynir Kjær Indahl and Johannes Hidle Lien. The firm is headquartered in Stockholm, Sweden.

Summa Equity AB (Summa Equity) is a private equity firm founded in 2016 by Jenny Keisu, Reynir Kjær Indahl and Johannes Hidle Lien. The firm is headquartered in Stockholm, Sweden.

Mérieux Equity Partners SAS (Mérieux Equity Partners or MxEP) is a Private Equity and Venture Capital firm, a subsidiary of Mérieux Développement SASU founded in 2009. The firm is headquartered in Lyon, France, with additional offices across the country.

Mérieux Equity Partners SAS (Mérieux Equity Partners or MxEP) is a Private Equity and Venture Capital firm, a subsidiary of Mérieux Développement SASU founded in 2009. The firm is headquartered in Lyon, France, with additional offices across the country.

Agendia, Inc. operates as a molecular diagnostics company. It develops and markets FFPE-based genomic diagnostic products, which help support physicians with their treatment decisions. Agendia?s tests can help physicians assess a patient?s individual risk for metastasis, it benefits from chemo, hormonal or combination therapy. The company was founded by Laura van't Veer and Ren? Bernards in 2003 and is headquartered in Irvine, CA.

Sengenics International Pte Ltd. develops arrays used in genomics research. It is a genomics and proteomics-based research and diagnostics company with a range of patented technologies and products that are marketed to pharmaceutical companies, scientists and hospitals. The firm flagship technology is the patented Immunome auto-antibody profiling platform which was spun out from research that was commercialized as a joint collaboration between the University of Oxford and the University of Cambridge. The company is headquartered in Singapore.

Summa Equity AB (Summa Equity) is a private equity firm founded in 2016 by Jenny Keisu, Reynir Kjær Indahl and Johannes Hidle Lien. The firm is headquartered in Stockholm, Sweden.

Korys Management NV is a Private Equity/Venture Capital firm, a subsidiary of Korys NV founded in 2000. Korys Management NV is headquartered in Halle.

Korys Management NV is a Private Equity/Venture Capital firm, a subsidiary of Korys NV founded in 2000. Korys Management NV is headquartered in Halle.

Agendia, Inc. operates as a molecular diagnostics company. It develops and markets FFPE-based genomic diagnostic products, which help support physicians with their treatment decisions. Agendia?s tests can help physicians assess a patient?s individual risk for metastasis, it benefits from chemo, hormonal or combination therapy. The company was founded by Laura van't Veer and Ren? Bernards in 2003 and is headquartered in Irvine, CA.

Agendia, Inc. operates as a molecular diagnostics company. It develops and markets FFPE-based genomic diagnostic products, which help support physicians with their treatment decisions. Agendia?s tests can help physicians assess a patient?s individual risk for metastasis, it benefits from chemo, hormonal or combination therapy. The company was founded by Laura van't Veer and Ren? Bernards in 2003 and is headquartered in Irvine, CA.

Summa Equity AB (Summa Equity) is a private equity firm founded in 2016 by Jenny Keisu, Reynir Kjær Indahl and Johannes Hidle Lien. The firm is headquartered in Stockholm, Sweden.

Mérieux Equity Partners SAS (Mérieux Equity Partners or MxEP) is a Private Equity and Venture Capital firm, a subsidiary of Mérieux Développement SASU founded in 2009. The firm is headquartered in Lyon, France, with additional offices across the country.

Mérieux Equity Partners SAS (Mérieux Equity Partners or MxEP) is a Private Equity and Venture Capital firm, a subsidiary of Mérieux Développement SASU founded in 2009. The firm is headquartered in Lyon, France, with additional offices across the country.

IQVIA MedTech NV develops and commercializes investigational products and therapies. Its services include project and site management, monitoring, auditing, and risk-based monitoring. The company was founded by Bert Segers and Aly Talen in 2005 and is headquartered in Antwerp, Belgium.

Agendia, Inc. operates as a molecular diagnostics company. It develops and markets FFPE-based genomic diagnostic products, which help support physicians with their treatment decisions. Agendia?s tests can help physicians assess a patient?s individual risk for metastasis, it benefits from chemo, hormonal or combination therapy. The company was founded by Laura van't Veer and Ren? Bernards in 2003 and is headquartered in Irvine, CA.

Mérieux Equity Partners SAS (Mérieux Equity Partners or MxEP) is a Private Equity and Venture Capital firm, a subsidiary of Mérieux Développement SASU founded in 2009. The firm is headquartered in Lyon, France, with additional offices across the country.

Korys Management NV is a Private Equity/Venture Capital firm, a subsidiary of Korys NV founded in 2000. Korys Management NV is headquartered in Halle.

Agendia, Inc. operates as a molecular diagnostics company. It develops and markets FFPE-based genomic diagnostic products, which help support physicians with their treatment decisions. Agendia?s tests can help physicians assess a patient?s individual risk for metastasis, it benefits from chemo, hormonal or combination therapy. The company was founded by Laura van't Veer and Ren? Bernards in 2003 and is headquartered in Irvine, CA.

Summa Equity AB (Summa Equity) is a private equity firm founded in 2016 by Jenny Keisu, Reynir Kjær Indahl and Johannes Hidle Lien. The firm is headquartered in Stockholm, Sweden.

Agendia, Inc. operates as a molecular diagnostics company. It develops and markets FFPE-based genomic diagnostic products, which help support physicians with their treatment decisions. Agendia?s tests can help physicians assess a patient?s individual risk for metastasis, it benefits from chemo, hormonal or combination therapy. The company was founded by Laura van't Veer and Ren? Bernards in 2003 and is headquartered in Irvine, CA.

Agendia, Inc. operates as a molecular diagnostics company. It develops and markets FFPE-based genomic diagnostic products, which help support physicians with their treatment decisions. Agendia?s tests can help physicians assess a patient?s individual risk for metastasis, it benefits from chemo, hormonal or combination therapy. The company was founded by Laura van't Veer and Ren? Bernards in 2003 and is headquartered in Irvine, CA.

IQVIA MedTech NV develops and commercializes investigational products and therapies. Its services include project and site management, monitoring, auditing, and risk-based monitoring. The company was founded by Bert Segers and Aly Talen in 2005 and is headquartered in Antwerp, Belgium.

Sengenics International Pte Ltd. develops arrays used in genomics research. It is a genomics and proteomics-based research and diagnostics company with a range of patented technologies and products that are marketed to pharmaceutical companies, scientists and hospitals. The firm flagship technology is the patented Immunome auto-antibody profiling platform which was spun out from research that was commercialized as a joint collaboration between the University of Oxford and the University of Cambridge. The company is headquartered in Singapore.

Summa Equity AB (Summa Equity) is a private equity firm founded in 2016 by Jenny Keisu, Reynir Kjær Indahl and Johannes Hidle Lien. The firm is headquartered in Stockholm, Sweden.